• $3M non-dilutive grant awarded to conduct studies in regional Australia
• Study aims to improve stroke care through telehealth-enabled emu⢠brain scanners
• Partners include Titan Pre-hospital Innovation, Australian Stroke Alliance and South Australian Rural Support Service

EMVision Medical Devices Limited (ASX:EMV) has been awarded $3 million in non-dilutive grant funding under the Cooperative Research Centres Projects (CRC-P) Round 17 grant program. The study will be conducted in South Australian regional hospitals, using EMVision's emu⢠point-of-care brain scanners enabled with telehealth (Titan Zeus) and dedicated stroke nurses, to demonstrate the ability to provide more timely diagnosis for stroke patients in resource-constrained communities. This is the first study to demonstrate the clinical benefit of the emu⢠device. The clinical benefit and health economic data derived from this study is intended to support the adoption and commercialisation of the emu⢠product. The partners on the grant submission include Titan Pre-hospital Innovation, Australian Stroke Alliance and South Australian Rural Support Service. The project team has been assembled to ensure a robust and informative outcome, leveraging expertise in diagnostic technology, digital health, stroke systems of care, and regional healthcare.

The funding available to EMVision from outstanding grants now totals $7.4 million.

EMVision intends to seek Australian regulatory clearance by leveraging prior FDA clearance, which expedites market launch. The company plans to seek market clearance once the in-progress pivotal trial (demonstrating diagnostic performance) has been completed.